Table I.

Characteristics of patients with AML.

UPN	FAB	Age	Sex	PBB (%)	WBC (g/l)	Hb (g/dl)	Plt (g/l)	Cytogenetics	Molecular markers	ELN cytogenetic risc group	NCCN cytogenetic risc group	AML blast characteristics
1	M5	81	M	60	61.3	11.7	72	46, XY	MLLT3/MLL t(9;11) n.d. CEBPA n.d., PML/RARA t(15;17) negative, RUNX1/RUNX1T1 t(8;21) negative, CBFB/MYH11 inv(16) negative, FLT3-ITD negative, FLT3-TKD wild-type, NPM1 mutation type A	Favorable	Better-risk	CD33+
2	M5	71	F	24	18.0	7.1	127	46, XX	MLLT3/MLL t(9;11) negative, CEBPA wild-type, PML/RARA t(15;17) negative, RUNX1/RUNX1T1 t(8;21) negative, CBFB/MYH11 inv(16) negative, FLT3-ITD negative, FLT3-TKD wild-type, NPM1 mutation type D	Favorable	Better-risk	CD33+

AML, acute myeloid leukemia; UPN, uniform patient number; FAB, French-American-British classification; F female; M, male; PBB, peripheral blood blasts among nucleated cells; WBC, white blood count; Hb, hemoglobin; Plt, platelets; ELN, European LeukemiaNet; NCCN, National Comprehensive Cancer Network; n.d., not determined.